Features Tuesday, April 07, 2015 - 05:30
The News Minute | February 18, 2015 | 02:54 pm IST  One 12-week course for the new hepatitis C virus (HCV) cure named Sofosbovir is selling under the brand name Sovaldi in the United States (US). Sovaldi is a breakthrough in science and Gilead, company that came up with it is rightfully raking in the profits and saving millions of lives.  But here’s the catch. Gilead set the price for a 12-week treatment course of Sovaldi at $84,000 or $1,000 per pill. According to researchers at Liverpool University, the actual production costs of Sovaldi for the 12-week course is $68 - $136. The generic sofosbuvir is currently being marketed in India at $300 per treatment course after India refused to grant Gilead a patent for the Indian market. “In other words, the US price –cost markup is roughly 1,000-to-1,” says noted economist and public health authority Dr. Jeffrey Sachs in The Huffington Post. In an article entitled The Drug That Is Bankrupting America, Sachs who is a Professor at the Earth Institute at the Columbia University says Sovaldi which is the poster child of a U.S. health care system that is being bankrupted by greed, lobbying and indefensible prices on drug pricing. Read full article here. Tweet
Become a TNM Member for just Rs 999!
You can also support us with a one-time payment.